Oragenics (NYSE:OGEN) Now Covered by StockNews.com

by · The Cerbat Gem

StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN – Free Report) in a research report report published on Wednesday morning. The brokerage issued a sell rating on the stock.

Oragenics Price Performance

NYSE OGEN opened at $0.40 on Wednesday. The company has a 50 day simple moving average of $0.92 and a 200-day simple moving average of $1.26. Oragenics has a 52-week low of $0.38 and a 52-week high of $7.74. The firm has a market capitalization of $1.78 million, a price-to-earnings ratio of -0.05 and a beta of 0.50.

Oragenics (NYSE:OGEN – Get Free Report) last released its earnings results on Friday, August 9th. The company reported ($0.51) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Oragenics

A hedge fund recently bought a new stake in Oragenics stock. Virtu Financial LLC purchased a new position in shares of Oragenics, Inc. (NYSE:OGEN – Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned about 0.51% of Oragenics as of its most recent SEC filing. Hedge funds and other institutional investors own 18.71% of the company’s stock.

About Oragenics

(Get Free Report)

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.

Featured Stories